OctreoPharm Sciences
Focused on the development of new radio pharmaceuticals for neuroendocrine tumors.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
€50.0m | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2010 | 2011 | 2012 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
OctreoPharm Sciences GmbH, established in Berlin, Germany in 2009, operated as a clinical-stage biopharmaceutical company focused on radiopharmaceuticals. The firm was dedicated to developing and commercializing radioactively labeled compounds for both molecular imaging and therapeutic uses, a strategy known as theranostics.
The company's core business revolved around creating solutions for the diagnosis and treatment of neuroendocrine tumors (NETs). Its main product development was centered on a theranostic approach using a somatostatin receptor antagonist peptide. This included a diagnostic compound for use as an imaging tool with positron emission tomography (PET), which was in clinical development. Simultaneously, a therapeutic compound, labeled with the radioisotope 177Lutetium (177Lu), was being developed for peptide receptor radionuclide therapy (PRRT) to treat NETs and was in the preclinical stage at the time of its acquisition.
In May 2015, the French pharmaceutical group Ipsen announced its acquisition of OctreoPharm Sciences. The deal was valued at up to approximately €50 million, consisting of an upfront payment and subsequent payments based on achieving specific clinical and regulatory milestones. This acquisition was a strategic move for Ipsen to expand its portfolio and reinforce its position in the neuroendocrine tumor market. As part of the agreement, Ipsen planned to retain the Berlin location and its staff to ensure a smooth transfer of expertise. The acquisition also included a contract manufacturing agreement with Eckert & Ziegler, one of OctreoPharm's shareholders, for the radio-labeling of the therapeutic compound.
Keywords: OctreoPharm Sciences, radiopharmaceuticals, theranostics, neuroendocrine tumors, molecular imaging, peptide receptor radionuclide therapy, somatostatin receptor antagonist, 177Lutetium, positron emission tomography, Ipsen acquisition, Eckert & Ziegler, clinical-stage biopharmaceutical, cancer diagnosis, cancer treatment, oncology, NET imaging, PRRT, radionuclide therapy, antagonist peptides, Berlin biotech